期刊文献+

益气补血方对化疗后小鼠T淋巴细胞增殖能力及细胞因子IL-2和IL-6分泌的影响 被引量:2

下载PDF
导出
摘要 目的:研究中药益气补血方对化疗后小鼠T淋巴细胞增殖能力及细胞因子分泌功能的影响。方法:40只雌性SPF级C57BL/6小鼠随机分为四组,即生理盐水组、化疗组(环磷酰胺腹腔注射)、益气补血方组(中药灌服)及益气补血方联合化疗组,给药2个疗程后处死小鼠,对各实验组小鼠骨髓细胞进行细胞周期分析,收集各实验组小鼠脾淋巴细胞体外培养,绘制T淋巴细胞生长曲线,并用ELISA法检测经肿瘤抗原刺激后的小鼠淋巴细胞分泌细胞因子IL-2和IL-6的情况。结果:益气补血方能有效缓解化疗造成的骨髓细胞G1期阻滞,提高G2/M期细胞比例及降低凋亡细胞数;细胞生长曲线显示益气补血方能对化疗后小鼠T淋巴细胞的增殖能力有一定保护作用,但未能恢复到对照组水平;益气补血方组小鼠淋巴细胞IL-2的分泌水平与对照组比较差异无显著性(P>0.05);在48 h检测点,益气补血方联合化疗组的IL-6表达水平虽有一定程度提高,但仍显著低于对照组(P<0.05)。结论:益气补血方具有减轻环磷酰胺化疗引起的小鼠骨髓抑制,保护小鼠淋巴细胞增殖及细胞因子分泌的作用。
出处 《中药材》 CAS CSCD 北大核心 2013年第2期287-291,共5页 Journal of Chinese Medicinal Materials
基金 广东省建设中医药强省科研课题(2010419) 国家自然科学基金(31100664)
  • 相关文献

参考文献10

  • 1王璐,吴凤麟,王金金,薄华本,黄树林.补血方对环磷酰胺所致小鼠血虚模型的影响[J].中药材,2009,32(3):414-416. 被引量:8
  • 2薄华本,王璐,王金全,陈启助,吴凤麟,邵宏伟,黄树林.补血方协同转染TCRVβ7.1 PBMC对肿瘤化疗造成骨髓抑制的缓解机制[J].中药材,2009,32(2):254-256. 被引量:2
  • 3颜强,张奕廷,张运来,黄志强.香菇多糖对胃癌患者术后化疗毒副作用的保护作用[J].南方医科大学学报,2008,28(1):147-148. 被引量:8
  • 4苏海涛,黄永明,许少健,石宇雄,徐逸生,刘金文.加味六味地黄汤对骨肉瘤化疗患者免疫功能的影响[J].南方医科大学学报,2010,30(6):1412-1414. 被引量:6
  • 5Bronte V, Kasic T, Gri G, et al. Boosting antitumor respon- ses of T lymphocytes infiltrating human prostate cancers [ J]. J Exp Med,2005,201 ( 8 ) : 1257-1268.
  • 6Brenner MK, Heslop HE. Adoptive T cell therapy of cancer [ J ]. Curr Opin Immunol,2010,22 (2) : 251-257.
  • 7Iguchi M, Matsumoto M, Hojo K, et al Antitumor efficacy of recombinant human interleukin-2 combined with sorafenib against mouse renal cell carcinoma [ J ]. Jpn J Clin Oncol, 2009,39 ( 5 ) :303-309.
  • 8Krieg C, L6toumeau S, Pantaleo G,et al. Improved IL-2 im- munotherapy by selective stimulation of IL-2 receptors on lymphocytes and endothelial cells [ J ]. Proc Natl Acad Sci USA, 2010,107 (26) : 11906-11911.
  • 9Berasain C, Perugorria M J, Latasa MU, et al. The epidermal growth factor receptor:a link between inflammation and liv- er cancer. [J] Exp Biol Med,2009,234(7) :713-725.
  • 1001dford SA, Haidl ID, Howatt MA, et al. A critical role formast cells and mast cell-derived IL-6 in TLR2-mediated inhibition of tumor growth [ J]. J Immunol, 2010, 185: 7067 -7076.

二级参考文献17

共引文献20

同被引文献45

  • 1熊艳,鲍继鹏.肝细胞癌患者化疗后血清中IL-6低水平持高的原因分析[J].医学研究生学报,2001,14(z1). 被引量:1
  • 2黄晓曦,王兴鹏,吴恺,马晶晶,徐铭益.肠屏障功能障碍临床评估指标建立的初步研究[J].中华消化杂志,2006,26(8):519-522. 被引量:38
  • 3王兴鹏.肠屏障功能障碍临床诊治建议[J].中华消化杂志,2006,26(9):620-620. 被引量:128
  • 4Briccoli A,Rocca M,Salone M,et al.High grade osteosarcoma of the extremities metastatic to the lung:long-term results in 323patients treated combining surgery and chemotherapy,1985-2005[J].Surg Oncol,2010,19(4):193-199.
  • 5Endo-Munoz L.,Cumming A.,Sommerville S.,et al.Osteosarcoma is characterised by reduced expression of markers of osteoclastogenesis and antigen presentation compared with normal bone[J].British journal of cancer,2010,103:73-81.
  • 6Jaffe N.Osteosarcbma:Review of the past,impact on the future.Thmerican experience[J].Cancer Treat Res,2010,152:239-262.
  • 7Mirabello,L,Troisi,R.J.&Savage,S.A.Osteosarcoma incidence and survival rates from 1973 to 2004:data from the Surveillance,Epidemiology,and End Results Program[J].Cancer,2009,115:1531-1543.
  • 8Parkes S.E.,Parke S.,Mangham D.C.,et al.Fifty years of paediatric malignant bone tumours in the West Midlands,UK,1957-2006:incidence,treatment and outcome[J].Paediatric and perinatal epidemiology,2010,24:470-478.
  • 9Meyers PA,Schwartz CL,Krailo MD,et al.Osteosarcoma:the addition of muramyl tripeptide to chemotherapy improves overall survival:a report from the Children's Oncology Group[J].J Clin Oncol,2008,26(4):633-638.
  • 10Sampo M.,Koivikko M.,Taskinen M.,et al.Incidence,epidemiology and treatment results of osteosarcoma in Finland-a nationwide population-based study[J].Acta Oncol,2011,50:1206-1214.

引证文献2

二级引证文献25

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部